Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBNYSE / NASDAQHealthcareSmall cap

$6.12-$0.20 (-3.2%)

Last close · Data as of Nov 20, 2026

Market cap
$559.2M
P/E
-8.4x
EV / EBITDA
-28.3x
Revenue
$201.5M
Net margin
-33.0%
ROCE
-10.5%

+17.5% over the last year

Cytek Biosciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+14.6%
3M
+31.3%
6M
+62.3%
1Y
+17.5%
5Y
-68.6%

52-week range

Day change -$0.20 (-3.2%) from $6.32 to $6.12 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CTKB, bought on each weekday since 2021.

News & filings

What Cytek Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 66.5 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 73.3% in fiscal 2025, 72.8 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.

Read moreShow less

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Sector
Healthcare
Shares outstanding
128.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$559.2M
P/E
-8.4x
P/B
1.6x
EV / EBITDA
-28.3x
EV / Sales
2.4x
P/S
2.8x
52-week high
$6.32
52-week low
$3.36

Profitability

Operating margin
-20.0%
Net margin
-33.0%
EBITDA margin
-8.6%
ROE
-19.5%
ROCE
-10.5%
ROA
-14.4%
Asset turnover
0.44

Growth

Revenue
$201.5M
Revenue growth, 1Y
0.5%
Revenue CAGR, 3Y
7.1%
Net profit growth, 1Y
1005.3%
Free cash flow
-$8.9M

Solvency

Current ratio
5.04
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
0.07
Cash / Market cap
16.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$201.5M
Cost of revenue$97.0M
Gross profit$104.5M
Operating expenses$144.8M
Research and development$36.5M
Selling, general and administrative$108.4M
Operating income-$40.4M
Interest and other$10.5M
Pretax income-$29.8M
Tax and other$36.7M
Net income-$66.5M

Revenue and net profit

Revenue grew 0.5% in FY2025; net profit is the dashed line.

Cytek Biosciences, Inc. revenue and net profit by fiscal year
Cytek Biosciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$164.0M$2.6M
FY2023$193.0M-$12.1M
FY2024$200.5M-$6.0M
FY2025$201.5M-$66.5M

Cash flows

FY2025: -$4.7M from operations, -$8.9M free after investment (dashed).

Cytek Biosciences, Inc. operating and free cash flow by fiscal year
Cytek Biosciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$12.2M-$22.1M
FY2023$5.3M$454.0k
FY2024$25.4M$21.6M
FY2025-$4.7M-$8.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$201.5M+0.5%1Y
EBITDA
-$17.4M
Net profit
-$66.5M
Cash from operations
-$4.7M-118.5%1Y
Free cash flow
-$8.9M-141.0%1Y
Revenue CAGR, 3Y
7.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$201.5M-$17.4M-$66.5M-$8.9M-19.5%+0.5%+1005.3%

Monthly returns

Month-by-month returns of CTKB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$461.5M
Liabilities$119.8M
Equity$341.7M
Paid-in capital$441.1M
Retained earnings-$101.7M
Minority interest$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CTKB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Cytek Biosciences, Inc. (this company)2.4x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cytek Biosciences, Inc.CTKBthis company$559.2M-8.4x1.6x-19.5%-28.3x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Rigel Pharmaceuticals, Inc.RIGL$559.7M1.5x1.4x93.8%4.4x
Ironwood Pharmaceuticals, Inc.IRWD$559.7M23.3x-2.1x-9.2%9.0x
Cerus CorporationCERS$559.0M—8.7x-24.3%—
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Peer median—1.5x2.4x-7.3%4.4x

Year-to-date ROI

CTKB since 1 January, against earlier years.

Historical volatility

CTKB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Cytek Biosciences, Inc. operating margin by fiscal year
Cytek Biosciences, Inc. operating margin by fiscal year
DateOperating margin
FY2022-1.1%
FY2023-14.4%
FY2024-10.2%
FY2025-20.0%
LineFY2025
Cost of revenueCost Of Revenue$97.0M
Gross profitGross Profit$104.5M
Operating expensesOperating Expense$144.8M
Research and developmentResearch And Development$36.5M
Total expensesTotal Expenses$241.9M
Pretax incomePretax Income-$29.8M

Learn while you research

Academy chapters picked for Cytek Biosciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →